CCMP Capital

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Retrieved on: 
Tuesday, November 28, 2023

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors.
  • “Geron’s tremendous science, expertise, clinical results and readiness to bring their first-in-class investigational telomerase inhibitor to the market have made this a very exciting time to join the Board,” said Dr. Aggarwal.
  • Dr. Aggarwal received his MD from Columbia University, College of Physicians & Surgeons, and his BS in Agricultural Economics from Cornell University.
  • Dr. Aggarwal will serve as an independent Board member for Geron; his appointment to the Geron Board was not associated with an investment made either by him or by any investment firm.

Executive Coach Jerry Colonna urges leaders to embrace inclusion in 'REUNION: Leadership and the Longing to Belong' (HarperBusiness, Nov. 14)

Retrieved on: 
Tuesday, November 14, 2023

NEW YORK, Nov. 14, 2023 /PRNewswire-PRWeb/ -- Leaders are increasingly challenged to understand how to respond to a polarized world. They are grappling with division while embracing otherness. But to create welcoming environments where all team members feel recognized and comfortable being their whole selves at work, leaders must first face their own need for belonging.

Key Points: 
  • NEW YORK, Nov. 14, 2023 /PRNewswire-PRWeb/ -- Leaders are increasingly challenged to understand how to respond to a polarized world.
  • But to create welcoming environments where all team members feel recognized and comfortable being their whole selves at work, leaders must first face their own need for belonging.
  • "Your mission is not just to be a better person or to make a better company, but to work towards creating a better world.
  • Jerry Colonna is a leading executive coach who uses the skills he learned as a venture capitalist to help entrepreneurs.

Normunity appoints industry leader Debanjan Ray to Board of Directors

Retrieved on: 
Monday, July 10, 2023

Normunity, Inc ., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced the appointment of Debanjan Ray, MBA, to its board of directors.

Key Points: 
  • Normunity, Inc ., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced the appointment of Debanjan Ray, MBA, to its board of directors.
  • Mr. Ray currently serves as President and Chief Executive Officer of Synthekine, and he has served in leadership roles for multiple biotechnology companies.
  • “We are excited to welcome Debanjan to our Board of Directors, as he brings exceptional strategic, operational, and transactional leadership as a CEO and senior executive who has played a critical role in building emerging biotech companies,” said Rachel Humphrey, MD, founding Chief Executive Officer of Normunity.
  • Prior to joining CytomX in 2011, Mr. Ray was VP of Business Development at Itero Biopharmaceuticals.

Electra Appoints Former Airbus, Boeing Executives and Aircraft Finance Leader to its Board

Retrieved on: 
Wednesday, May 31, 2023

Electra delivers the most flexible, efficient and cost-effective solution for the $150B Advanced Air Mobility market.

Key Points: 
  • Electra delivers the most flexible, efficient and cost-effective solution for the $150B Advanced Air Mobility market.
  • "I am thrilled to welcome Jim, Allan, and Kirsten to the Electra Board at this important time in the development of our eSTOL aircraft.
  • They bring deep understanding of the industry and an invaluable perspective on aircraft development, operation, finance, and regulation to the team."
  • He also served as President of Rocketdyne Propulsion & Power, President of Boeing Space and Communications, and President of Boeing Integrated Defense Systems.

Hillman Announces Directors from Private Equity Firm Step Down from Board Following Final Share Sale

Retrieved on: 
Friday, May 12, 2023

The change follows CCMP, a private equity firm, exiting its position in Hillman’s stock through a secondary offering, which is expected to close on May 15, 2023.

Key Points: 
  • The change follows CCMP, a private equity firm, exiting its position in Hillman’s stock through a secondary offering, which is expected to close on May 15, 2023.
  • During the offering, CCMP sold its remaining 22,455,000 shares and is no longer a shareholder.
  • Since CCMP’s initial investment in Hillman in 2014, sales have doubled to approximately $1.5 billion in 2022.
  • We are grateful for the support and investments from CCMP, which were vital to our growth and success.

EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team

Retrieved on: 
Monday, March 6, 2023

The Company also announced details on Restoret™, the first asset in a diversified pipeline of multi-specific agonist antibodies.

Key Points: 
  • The Company also announced details on Restoret™, the first asset in a diversified pipeline of multi-specific agonist antibodies.
  • “We founded EyeBio to capture scientific advances and translate them into effective treatments for patients with serious eye diseases,” said David Guyer, M.D., co-founder, CEO, and president of EyeBio.
  • “The world-class team we have assembled gives us the talent and resources to continue our rapid progress and success in advancing a strong pipeline.
  • These assets signal a diverse pipeline that leverages a core strength in developing multi-specific antibodies and intravitreal retinal therapies.

Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors

Retrieved on: 
Tuesday, July 26, 2022

We are thrilled to welcome Dr. Akkaraju to Scholar Rocks Board of Directors as we continue to expand upon our diverse network of experienced biotechnology company-builders, said Nagesh Mahanthappa, Ph.D., Founding Chief Executive Officer & President of Scholar Rock.

Key Points: 
  • We are thrilled to welcome Dr. Akkaraju to Scholar Rocks Board of Directors as we continue to expand upon our diverse network of experienced biotechnology company-builders, said Nagesh Mahanthappa, Ph.D., Founding Chief Executive Officer & President of Scholar Rock.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
  • Scholar Rock is a registered trademark of Scholar Rock, Inc.
  • All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.

A-LIGN Introduces New Board of Directors to Guide Company Through Next Phase of Growth

Retrieved on: 
Wednesday, February 2, 2022

TAMPA, Fla., Feb. 2, 2022 /PRNewswire/ --Following a year of tremendous growth and investment, cybersecurity and compliance audit firm A-LIGNis introducing its new board of directors.

Key Points: 
  • TAMPA, Fla., Feb. 2, 2022 /PRNewswire/ --Following a year of tremendous growth and investment, cybersecurity and compliance audit firm A-LIGNis introducing its new board of directors.
  • The additional board of directors follows a strategic investment in A-LIGN by Warburg Pincus , a leading global growth investor, in August 2021.
  • Brian Changis a Managing Director, focusing on investments in the technology, software, information, and financial technology sectors at Warburg Pincus.
  • A-LIGN welcomes the combined years of experience and expertise this team brings to its board as the company looks to expand its SaaS offering.

Concentric Analgesics Announces Completion of $20 Million Financing and Appoints Two New Board Members as it Prepares to Initiate Registration-Enabling Phase 3 Studies for Vocacapsaicin

Retrieved on: 
Wednesday, January 26, 2022

In addition, the company announced the appointments of Paul R. Carter and Jonathan R. Lynch to its board of directors.

Key Points: 
  • In addition, the company announced the appointments of Paul R. Carter and Jonathan R. Lynch to its board of directors.
  • Concentric intends to use the proceeds from the financing to further fund Phase 3 development activities for vocacapsaicin, its lead therapeutic candidate for postsurgical pain.
  • Mr. Carter is currently a Board Director for four publicly listed biopharma companies, which include HutchMed PLC, Mallinckrodt Pharmaceuticals plc, Immatics NV, and VectivBio Inc.
  • He also is a member of the board of directors of several private companies, including Evox Therapeutics Ltd.

UDR Appoints Kevin C. Nickelberry to Board of Directors

Retrieved on: 
Monday, September 13, 2021

UDR, Inc. (the "Company") (NYSE: UDR), a leading multifamily real estate investment trust, today announced the appointment of Kevin C. Nickelberry to its Board of Directors effective September 10, 2021.

Key Points: 
  • UDR, Inc. (the "Company") (NYSE: UDR), a leading multifamily real estate investment trust, today announced the appointment of Kevin C. Nickelberry to its Board of Directors effective September 10, 2021.
  • We are excited to welcome Kevin to UDRs Board, said Jim Klingbeil, Lead Independent Director and Chairman of the Nominating Committee.
  • Mr. Klingbeil continued, Kevin is a highly accomplished senior executive with valued expertise in human capital management, corporate governance, and capital allocation and strategy.
  • He is a current member of the Board of Directors of the Northside Center for Child Development in New York City.